Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
The concurrent use of metformin with the tyrosine kinase inhibitor (TKI) gefitinib does more harm than good, resulting in significantly worse outcomes and increasing the risk of diarrhoea in nondiabetic patients with nonsmall cell lung cancer (NSCLC) harbouring EFGR mutation, according to data from a phase II trial.
In the treatment of patients with advanced/metastatic nonsmall cell lung cancer (NSCLC), the combination of pembrolizumab plus vorinostat has a tolerable safety profile and demonstrates preliminary antitumour activity despite progression on prior immune checkpoint inhibitor (ICI) therapy, according to the results of a phase I/Ib trial.
First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.
Treatment of non-small-cell lung cancer (NSCLC) provides significant overall survival (OS) benefit in patients aged ≥90 years and should not be withheld based on old age alone, according to an analysis of data from the US National Cancer Database.
Adding pembrolizumab to platinum-based chemotherapy significantly improved survival and response to treatment compared with chemotherapy alone in the first-line setting for Chinese patients with metastatic, squamous non–small-cell lung cancer (NSCLC), according to the KEYNOTE-407* China Extension Study presented at the ESMO Asia 2019 Congress.
Crizotinib proves to be effective against nonsmall-cell lung cancer (NSCLC) with ROS-1 translocations and has modest activity in c-MET >6 copies and c-MET mutations, according to the results of the phase II AcSé trial.
Combining gefitinib with pemetrexed and carboplatin confers significant survival benefits in patients with nonsmall-cell lung cancer (NSCLC) that harbour an epidermal growth factor receptor (EGFR) mutation, extending progressive-free and overall survival although at the expense of increased toxicity, according to the results of an open-label phase III trial.
Blood-first next-generation sequencing leads to identification of ALK fusions in patients with nonsmall cell lung cancer, which in turn guides treatment decision-making, according to the initial results of the phase II/III B-FAST* trial presented at the European Society for Medical Oncology (ESMO) Congress 2019.
Radiation heart dosimetric parameters appear to exert neutral effect on overall survival (OS) in nonsmall cell lung cancer patients undergoing postoperative thoracic radiotherapy (PORT), according to a recent Singapore study.
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.